Active Surveillance or Another Prostate Cancer Treatment? Choices Linked to Quality of Life
Active surveillance of low-risk prostate cancer is as good as treating it in many cases, and spares patients such distressing treatment side
The ASCENDE-RT Study
The ASCENDE-RT (Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy) study was the first randomized clini
Intermediate risk prostate cancer may be well controlled with brachytherapy alone
For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer
Brachytherapy alone for intermediate-risk prostate cancer
A new study has found that men with intermediate-risk prostate cancer can be safely and effectively treated with radioactive-seed brachyther
‘Robotic surgery for prostate cancer no better than traditional surgery’
In recent years there’s been a huge increase in investment in robotic surgery to treat localised prostate cancer. However a landmark study published in the Lancet has shown that robotic surgery is no more effective than traditional surgery. Spending on robotic surgery for prostate cancer treatment has reached epic proportions, both from health care systems and patients in many countries. Despite its unprecedented growth the technology has been adopted without any high-level e
LDR brachytherapy has emerged as the most effective treatment for long-term survival of prostate can
Seed or LDR Brachytherapy has emerged as the most effective treatment for long- term survival of prostate cancer
Recent Study Favors Brachytherapy in Treating Prostate Cancer
Recent study concludes that permanent low-dose-rate brachytherapy is as effective in the treatment of low to intermediate risk prostate cancer as external beam radiation therapy (EBRT), but is less toxic. Brachytherapy treatment is also far less costly. A study carried out by the Cleveland Clinic between 1996 and 2007 looked at the data from 1,989 of their prostate cancer patients treated by permanent low-dose-rate brachytherapy monotherapy. The patients had a median age of 6
Hemiablative focal brachytherapy pilot study
Whole gland LDR brachytherapy has been a well established modality of treating low risk prostate cancer. Treatment in a focal manner has the
Cleveland clinic study favours brachytherapy in treating prostate cancer
Perversely brachytherapy is in decline in many countries when the results and costs are overwhelmingly in favour of this treatment.
Family history of prostate cancer doesn't mean higher risk of aggressive cancer
If you have a family history of prostate cancer, it does not mean you have a higher risk of aggressive prostate cancer.
